Offering hope to patients and their families is at the heart of the delivery of medicine. For families caring for a rare disease patient, that means having reliable access to the critical medications they need.
During this year’s Channel Management Forum, Wendy White, Chairman of Global Genes Foundation, delivered an overview on patient-centered strategy and innovation from the perspective of an entrepreneur, technologist and mother of a child with a rare disease. White provided valuable insights on the rapidly growing rare disease market and how to approach it with the end benefit to the patient in mind. The orphan drug market is projected to grow to $209 billion by 2022, with prescription sales rising 21.4 percent—twice the pace of non-orphan drugs. This rapid growth makes it more and more likely that you or a colleague may find yourself working on a rare disease product. How do the dynamics for delivering medicine change when the disease is rare? What lessons can be applied to traditional therapies?
Understanding where the patient is and starting from that point changes how we think about delivering these high-value therapies with urgency, efficiency and compassion. Rare disease patients succeed with coordinated care, including the attentive and timely delivery of their essential medicines. Cardinal Health 3PL supports pharma companies and healthcare providers serving rare disease patients and their families. We can help you evaluate distribution strategies based on the unique characteristics of your product, patients and providers, including direct distribution to the point of care and collaboration with the Cardinal Health Sonexus™ Access & Patient Support team.
For more rare disease insights, watch Wendy’s presentation from Channel Management Forum: